{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:15:29Z","timestamp":1789607729885,"version":"build-2803163510"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Poliovirus eradication efforts have relied on effective vaccination campaigns and stringent laboratory containment of poliovirus strains. Serological testing is the primary means to address population immunity, vaccine efficacy, and individual poliovirus exposures. However, strict containment requirements for Sabin type 2 and wild poliovirus types 2 &amp; 3 limit access to serological testing. To address these limitations, we evaluated the performance of hyper-attenuated, temperature-sensitive S19 poliovirus strains (S19-PV), which retain the antigenic characteristics of Sabin and Salk strains but can be handled under biosafety level 2 (BSL-2) conditions. Using a modified microneutralization assay, we performed a comparative validation of S19-PVs to their Sabin and wild-type counterparts using WHO international standards, in-house control reagents, and human sera. Neutralizing antibody titers showed strong concordance between S19-PV and reference strains (R\u00b2\u2009=\u20090.93\u20130.99), with high intra- and inter-assay reproducibility (CVs\u2009&lt;\u200910%). Our findings demonstrate that S19-PV strains are antigenically equivalent to Sabin and wild-type viruses and suitable for use in neutralization assays to determine levels of poliovirus neutralizing antibodies outside of strict containment laboratories. Adoption of these strains can significantly expand global capacity for poliovirus serological testing, supporting surveillance and immunization activities in the final stages of poliovirus eradication.<\/jats:p>","DOI":"10.1371\/journal.pone.0343816","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T18:48:57Z","timestamp":1771872537000},"page":"e0343816","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of hyper-attenuated S19 poliovirus strains for use in poliovirus neutralization assays"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8272-4982","authenticated-orcid":true,"given":"Nicholas","family":"Wiese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Hendley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basit","family":"Jafri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn A.V.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Sifontes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Valdez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7721-183X","authenticated-orcid":true,"given":"Bernardo A.","family":"Mainou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"issue":"1","key":"pone.0343816.ref001","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev-virology-101416-041749","article-title":"Breaking the Last Chains of Poliovirus Transmission: Progress and Challenges in Global Polio Eradication","volume":"5","author":"O Kew","year":"2018","journal-title":"Annu Rev Virol"},{"key":"pone.0343816.ref002","first-page":"840","article-title":"Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses","volume":"1","author":"M Pallansch","year":"2006","journal-title":"Fields virology"},{"key":"pone.0343816.ref003","volume-title":"n. Epidemiology and prevention of vaccine-preventable diseases: Department of Health & Human Services, Public Health Service, Centers for Disease Control and Prevention","author":"Centers for Disease Control and Preventio","year":"2005"},{"issue":"11","key":"pone.0343816.ref004","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/aje\/kwq320","article-title":"From emergence to eradication: the epidemiology of poliomyelitis deconstructed","volume":"172","author":"N Nathanson","year":"2010","journal-title":"Am J Epidemiol"},{"key":"pone.0343816.ref005","article-title":"The biologic principles of poliovirus eradication","author":"WR Dowdle","year":"1997","journal-title":"J Infect Dis"},{"issue":"5","key":"pone.0343816.ref006","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2105\/AJPH.44.5.563","article-title":"Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines","volume":"44","author":"JE Salk","year":"1954","journal-title":"Am J Public Health Nations Health"},{"issue":"5123","key":"pone.0343816.ref007","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1136\/bmj.1.5123.663","article-title":"Present position of immunization against poliomyelitis with live virus vaccines","volume":"1","author":"AB Sabin","year":"1959","journal-title":"Br Med J"},{"issue":"12","key":"pone.0343816.ref008","first-page":"222","article-title":"Apparent global interruption of wild poliovirus type 2 transmission","volume":"50","author":"Centers for Disease Control and Prevention (CDC)","year":"2001","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"18","key":"pone.0343816.ref009","doi-asserted-by":"crossref","first-page":"470","DOI":"10.15585\/mmwr.mm6518a4","article-title":"Progress Toward Polio Eradication - Worldwide, 2015-2016","volume":"65","author":"M Morales","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"45","key":"pone.0343816.ref010","first-page":"1031","article-title":"Possible eradication of wild poliovirus type 3--worldwide, 2012","volume":"63","author":"OM Kew","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"19","key":"pone.0343816.ref011","doi-asserted-by":"crossref","first-page":"441","DOI":"10.15585\/mmwr.mm7319a4","article-title":"Progress Toward Poliomyelitis Eradication - Worldwide, January 2022-December 2023","volume":"73","author":"K Geiger","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"pone.0343816.ref012","article-title":"Vaccine-derived polioviruses","author":"CC Burns","year":"2014","journal-title":"J Infect Dis"},{"issue":"20","key":"pone.0343816.ref013","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.vaccine.2009.02.071","article-title":"Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication","volume":"27","author":"P Minor","year":"2009","journal-title":"Vaccine"},{"key":"pone.0343816.ref014","volume-title":"WHO Global Action Plan for Poliovirus Containment","author":"World Health Organization","year":"2022","edition":"4"},{"key":"pone.0343816.ref015","author":"Centers for Disease Control and Prevention","year":"2024"},{"issue":"12","key":"pone.0343816.ref016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005316","article-title":"New strains intended for the production of inactivated polio vaccine at low-containment after eradication","volume":"11","author":"S Knowlson","year":"2015","journal-title":"PLoS Pathog"},{"issue":"7","key":"pone.0343816.ref017","doi-asserted-by":"crossref","DOI":"10.1128\/mra.00080-24","article-title":"Complete genome sequences of six S19 poliovirus reference strains","volume":"13","author":"CJ Castro","year":"2024","journal-title":"Microbiol Resour Announc"},{"key":"pone.0343816.ref018","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1111\/trf.15048","article-title":"Continued use of poliovirus after eradication: hyper-attenuated strains as a safe alternative for release testing of human immunoglobulins","author":"MR Farcet","year":"2018","journal-title":"Transfusion"},{"issue":"8","key":"pone.0343816.ref019","doi-asserted-by":"crossref","first-page":"4827","DOI":"10.1128\/JVI.77.8.4827-4835.2003","article-title":"Complexes of poliovirus serotypes with their common cellular receptor, CD155","volume":"77","author":"Y He","year":"2003","journal-title":"J Virol"},{"issue":"6","key":"pone.0343816.ref020","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1128\/JVI.80.6.2641-2653.2006","article-title":"Antigenic evolution of vaccine-derived polioviruses: changes in individual epitopes and relative stability of the overall immunological properties","volume":"80","author":"ML Yakovenko","year":"2006","journal-title":"J Virol"},{"key":"pone.0343816.ref021","doi-asserted-by":"crossref","first-page":"2","DOI":"10.11604\/pamj.supp.2023.45.2.38098","article-title":"Seroprevalence of poliovirus antibodies in Nigeria: refining strategies to sustain the eradication effort","volume":"45","author":"O Bolu","year":"2023","journal-title":"Pan Afr Med J"},{"key":"pone.0343816.ref022","doi-asserted-by":"crossref","first-page":"126978","DOI":"10.1016\/j.vaccine.2025.126978","article-title":"Impact of novel Oral Poliovirus Type 2 vaccination campaigns: A seroprevalence survey in Nigeria, 2022","volume":"54","author":"Z Iliyasu","year":"2025","journal-title":"Vaccine"},{"key":"pone.0343816.ref023","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1186\/s12889-016-3386-1","article-title":"Seroprevalence of poliovirus antibodies in the United States population, 2009-2010","volume":"16","author":"GS Wallace","year":"2016","journal-title":"BMC Public Health"},{"issue":"3","key":"pone.0343816.ref024","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/infdis\/jiae006","article-title":"Mucosal immunity to poliovirus in children 0-15 Years of Age: a community-based study in Karachi, Pakistan in 2019","volume":"230","author":"AF Saleem","year":"2024","journal-title":"J Infect Dis"},{"issue":"4","key":"pone.0343816.ref025","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(24)00552-7","article-title":"Three-dose immunogenicity of the type 2 novel oral poliovirus vaccine in a campaign setting in Tajikistan: a follow-up study","volume":"13","author":"A Mirzoev","year":"2025","journal-title":"Lancet Glob Health"},{"issue":"10432","key":"pone.0343816.ref026","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(23)02844-1","article-title":"Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial","volume":"403","author":"M Ochoge","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"pone.0343816.ref027","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(23)00519-4","article-title":"Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican Republic","volume":"24","author":"L Rivera Mej\u00eda","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"pone.0343816.ref028","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-1-4939-3292-4_8","article-title":"Standardized methods for detection of poliovirus antibodies","volume":"1387","author":"WC Weldon","year":"2016","journal-title":"Methods Mol Biol"},{"issue":"11","key":"pone.0343816.ref029","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1128\/CVI.05225-11","article-title":"Development of a poliovirus neutralization test with poliovirus pseudovirus for measurement of neutralizing antibody titer in human serum","volume":"18","author":"M Arita","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"pone.0343816.ref030","volume-title":"Polio Laboratory Manual","author":"Organization World Health","year":"2004","edition":"4"},{"key":"pone.0343816.ref031","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.biologicals.2018.03.001","article-title":"Establishment of the 1st WHO International Standard for anti-EV71 serum (Human)","volume":"53","author":"G Cooper","year":"2018","journal-title":"Biologicals"},{"issue":"4","key":"pone.0343816.ref032","first-page":"517","article-title":"The formation and properties of poliovirus-neutralizing antibody. Iv. Normal antibody and early immune antibody of rabbit origin: A comparison of biological and physicochemical properties","volume":"119","author":"SE Svehag","year":"1964","journal-title":"J Exp Med"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0343816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T18:49:02Z","timestamp":1771872542000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0343816"}},"subtitle":[],"editor":[{"given":"Ma\u00ebl","family":"Bessaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0343816","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]}}}